Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469116 · ClinicalTrials.gov registry record · Phase 2
Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02469116 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 18 participants.
The verdict
NCT02469116, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
In this study the investigators will be using an AUC of 6 based on creatinine clearance using the Carboplatin dosing formula used for Gynecologic Oncology Group protocols. Given that myelosuppression was significant using the docetaxel dose of 75 mg/m\*2 in the SCOTROC trial, the prophylactic use of pegylated G-CSF in this Phase II trial is warranted. The expectation would be that patients will be able to receive their cycles in a more timely fashion, with less delays, thereby allowing for improved outcomes and decreased hospitalizations due to myelosuppression.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Pegylated G-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02469116
The ClinicalTrials.gov registry entry for NCT02469116 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02469116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02469116 about?
NCT02469116 is a clinical study titled "Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma". In this study the investigators will be using an AUC of 6 based on creatinine clearance using the Carboplatin dosing formula used for Gynecologic Oncology Group protocols. Given that myelosuppression was significant using the docetaxel dose of 75 mg/m\*2 in the SCOTROC trial, the prophylactic use o...
What is the current status of trial NCT02469116?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2006-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT02469116?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Pegylated G-CSF (DRUG).
Who is sponsoring clinical trial NCT02469116?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.